Nova Eye Medical (ASX:EYE) said the success rate in intraocular pressure reduction in patients with baseline intraocular pressure greater than 18 millimeters of mercury (mmHg) was 85% in its 2025 statistical report on progress of patients in the iTrack Global Data Registry, an independently managed database, according to a Tuesday Australian bourse filing.

Over 400 eyes reached the 12-month follow-up point under the registry, the filing said. Patients experienced a mean 40% reduction in medication burden across the group. There were six reported adverse events.

The outcomes were considered clinically meaningful, per the filing, compared with other minimally invasive glaucoma surgery procedures.

Nova Eye Medical's shares rose nearly 3% in recent trading on Tuesday.